The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis

Central nervous system (CNS) involvement is a serious complication in patients with diffuse large B-cell lymphoma (DLBCL) and evaluating CNS risk is an important issue. Using the standard international prognostic index (IPI) and CNS-IPI, a recently proposed model including IPI risk factors and adren...

Full description

Saved in:
Bibliographic Details
Published inLeukemia & lymphoma Vol. 59; no. 1; pp. 97 - 104
Main Authors Tomita, Naoto, Yokoyama, Masahiro, Yamamoto, Wataru, Watanabe, Reina, Shimazu, Yutaka, Masaki, Yasufumi, Tsunoda, Saburo, Hashimoto, Chizuko, Murayama, Kayoko, Yano, Takahiro, Okamoto, Rumiko, Kikuchi, Ako, Tamura, Kazuo, Sato, Kazuya, Sunami, Kazutaka, Shibayama, Hirohiko, Takimoto, Rishu, Ohshima, Rika, Takahashi, Hiromichi, Moriuchi, Yukiyoshi, Kinoshita, Tomohiro, Yamamoto, Masahide, Numata, Ayumi, Nakajima, Hideaki, Miura, Ikuo, Takeuchi, Kengo
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 02.01.2018
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Central nervous system (CNS) involvement is a serious complication in patients with diffuse large B-cell lymphoma (DLBCL) and evaluating CNS risk is an important issue. Using the standard international prognostic index (IPI) and CNS-IPI, a recently proposed model including IPI risk factors and adrenal/kidney involvement, we assessed CNS risk in 1220 untreated DLBCL patients who received R-CHOP without prophylaxis. According to the standard IPI, the cumulative incidences of CNS involvement at 2 years were 1.3, 4.6, 8.8, and 12.7% in the low-, low-intermediate-, high-intermediate-, and high-risk groups, respectively (p <.001). This result is comparable with that of the CNS-IPI. Patients with breast involvement tended to have lower risk according to the standard IPI but showed frequent CNS involvement, similar to patients with testis involvement. The standard IPI is also a useful predictor of CNS involvement. Patients with breast/testis involvement would be candidates for prophylaxis regardless of the standard IPI risk.
AbstractList Central nervous system (CNS) involvement is a serious complication in patients with diffuse large B-cell lymphoma (DLBCL) and evaluating CNS risk is an important issue. Using the standard international prognostic index (IPI) and CNS-IPI, a recently proposed model including IPI risk factors and adrenal/kidney involvement, we assessed CNS risk in 1220 untreated DLBCL patients who received R-CHOP without prophylaxis. According to the standard IPI, the cumulative incidences of CNS involvement at 2 years were 1.3, 4.6, 8.8, and 12.7% in the low-, low-intermediate-, high-intermediate-, and high-risk groups, respectively (p <.001). This result is comparable with that of the CNS-IPI. Patients with breast involvement tended to have lower risk according to the standard IPI but showed frequent CNS involvement, similar to patients with testis involvement. The standard IPI is also a useful predictor of CNS involvement. Patients with breast/testis involvement would be candidates for prophylaxis regardless of the standard IPI risk.
Central nervous system (CNS) involvement is a serious complication in patients with diffuse large B-cell lymphoma (DLBCL) and evaluating CNS risk is an important issue. Using the standard international prognostic index (IPI) and CNS-IPI, a recently proposed model including IPI risk factors and adrenal/kidney involvement, we assessed CNS risk in 1220 untreated DLBCL patients who received R-CHOP without prophylaxis. According to the standard IPI, the cumulative incidences of CNS involvement at 2 years were 1.3, 4.6, 8.8, and 12.7% in the low-, low-intermediate-, high-intermediate-, and high-risk groups, respectively (p &lt;.001). This result is comparable with that of the CNS-IPI. Patients with breast involvement tended to have lower risk according to the standard IPI but showed frequent CNS involvement, similar to patients with testis involvement. The standard IPI is also a useful predictor of CNS involvement. Patients with breast/testis involvement would be candidates for prophylaxis regardless of the standard IPI risk.
Author Tamura, Kazuo
Okamoto, Rumiko
Watanabe, Reina
Numata, Ayumi
Takeuchi, Kengo
Ohshima, Rika
Takahashi, Hiromichi
Yamamoto, Wataru
Yokoyama, Masahiro
Kinoshita, Tomohiro
Sunami, Kazutaka
Shibayama, Hirohiko
Miura, Ikuo
Yano, Takahiro
Shimazu, Yutaka
Moriuchi, Yukiyoshi
Murayama, Kayoko
Tomita, Naoto
Masaki, Yasufumi
Kikuchi, Ako
Hashimoto, Chizuko
Tsunoda, Saburo
Takimoto, Rishu
Sato, Kazuya
Nakajima, Hideaki
Yamamoto, Masahide
Author_xml – sequence: 1
  givenname: Naoto
  surname: Tomita
  fullname: Tomita, Naoto
  email: cavalier@ch-yamate.dlenet.com
  organization: Department of Hematology and Clinical Immunology, Yokohama City University Graduate School of Medicine
– sequence: 2
  givenname: Masahiro
  surname: Yokoyama
  fullname: Yokoyama, Masahiro
  organization: Ganken Ariake Lymphoma Study Group
– sequence: 3
  givenname: Wataru
  surname: Yamamoto
  fullname: Yamamoto, Wataru
  organization: Department of Medical Oncology, Kanagawa Cancer Center
– sequence: 4
  givenname: Reina
  surname: Watanabe
  fullname: Watanabe, Reina
  organization: Department of Hematology and Clinical Immunology, Yokohama City University Graduate School of Medicine
– sequence: 5
  givenname: Yutaka
  surname: Shimazu
  fullname: Shimazu, Yutaka
  organization: Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University
– sequence: 6
  givenname: Yasufumi
  surname: Masaki
  fullname: Masaki, Yasufumi
  organization: Department of Hematology and Immunology, Kanazawa Medical University
– sequence: 7
  givenname: Saburo
  surname: Tsunoda
  fullname: Tsunoda, Saburo
  organization: Division of Hematology, Tochigi Cancer Center
– sequence: 8
  givenname: Chizuko
  surname: Hashimoto
  fullname: Hashimoto, Chizuko
  organization: Department of Medical Oncology, Kanagawa Cancer Center
– sequence: 9
  givenname: Kayoko
  surname: Murayama
  fullname: Murayama, Kayoko
  organization: Department of Hematology, Gunma Cancer Center
– sequence: 10
  givenname: Takahiro
  surname: Yano
  fullname: Yano, Takahiro
  organization: Division of Hematology, Department of Internal Medicine, National Tokyo Medical Center, National Hospital Organization
– sequence: 11
  givenname: Rumiko
  surname: Okamoto
  fullname: Okamoto, Rumiko
  organization: Department of Chemotherapy, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital
– sequence: 12
  givenname: Ako
  surname: Kikuchi
  fullname: Kikuchi, Ako
  organization: Department of Hematology/Oncology, Tokai University School of Medicine
– sequence: 13
  givenname: Kazuo
  surname: Tamura
  fullname: Tamura, Kazuo
  organization: Department of Medicine, Division of Medical Oncology, Hematology, and Infectious Diseases, School of Medicine, Fukuoka University
– sequence: 14
  givenname: Kazuya
  surname: Sato
  fullname: Sato, Kazuya
  organization: Division of Hematology, Department of Medicine, Jichi Medical University
– sequence: 15
  givenname: Kazutaka
  surname: Sunami
  fullname: Sunami, Kazutaka
  organization: Department of Hematology, National Hospital Organization, Okayama Medical Center
– sequence: 16
  givenname: Hirohiko
  surname: Shibayama
  fullname: Shibayama, Hirohiko
  organization: Department of Hematology and Oncology, Osaka University Graduate School of Medicine
– sequence: 17
  givenname: Rishu
  surname: Takimoto
  fullname: Takimoto, Rishu
  organization: Fourth Department of Internal Medicine, Sapporo Medical University School of Medicine
– sequence: 18
  givenname: Rika
  surname: Ohshima
  fullname: Ohshima, Rika
  organization: Department of Hematology, Yokohama City University Medical Center
– sequence: 19
  givenname: Hiromichi
  surname: Takahashi
  fullname: Takahashi, Hiromichi
  organization: Department of Hematology and Rheumatology, Nihon University School of Medicine
– sequence: 20
  givenname: Yukiyoshi
  surname: Moriuchi
  fullname: Moriuchi, Yukiyoshi
  organization: Department of Internal Medicine, Sasebo City General Hospital
– sequence: 21
  givenname: Tomohiro
  surname: Kinoshita
  fullname: Kinoshita, Tomohiro
  organization: Department of Hematology and Oncology, Nagoya University Graduate School of Medicine
– sequence: 22
  givenname: Masahide
  surname: Yamamoto
  fullname: Yamamoto, Masahide
  organization: Department of Hematology, Tokyo Medical and Dental University
– sequence: 23
  givenname: Ayumi
  surname: Numata
  fullname: Numata, Ayumi
  organization: Department of Hematology/Immunology, Fujisawa City Hospital
– sequence: 24
  givenname: Hideaki
  surname: Nakajima
  fullname: Nakajima, Hideaki
  organization: Department of Hematology and Clinical Immunology, Yokohama City University Graduate School of Medicine
– sequence: 25
  givenname: Ikuo
  surname: Miura
  fullname: Miura, Ikuo
  organization: Division of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine
– sequence: 26
  givenname: Kengo
  surname: Takeuchi
  fullname: Takeuchi, Kengo
  organization: Pathology Project for Molecular Targets, Cancer Institute Japanese Foundation for Cancer Research
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28593796$$D View this record in MEDLINE/PubMed
BookMark eNp9kM1OJCEUhYnR-P8ITli6qR6gqB92jq0zY9LRhbomFNyyGaugB2i1Ex9eOt26dMUN97vnJN8R2nXeAUJnlEwoaclPSjhrqeATRmgzoWVJKk530CElTBSMk3J3PXNWrKEDdBTjP0JIJWq2jw5YW4myEfUhen-YA45JOaOCwdYlCE4l650a8CL4J-djsjovDLzh3of8CcbqZN0TTvk02PiMfY-nt_cZevHDC4zgUp7x1exyOsOvNs39MuG4AG37HJVTF_PVoN5sPEF7vRoinG7fY_T4-_ph-reY3f25mf6aFZqXLBU1N5z30LCOCcPargYuWtI0JWOadUIbKkyllKi7qlWCA1GUcgGNpl3TVqQuj9H5Jjd3_19CTHK0UcMwKAd-GSUVJIdRUbUZrTaoDj7GAL1cBDuqsJKUyLV4-SlersXLrfh892NbsexGMF9Xn6YzcLEBrMsaR_Xqw2BkUqvBhz4op22U5fcdH6xKlSo
CitedBy_id crossref_primary_10_1186_s40164_023_00467_2
crossref_primary_10_1111_bjh_16866
crossref_primary_10_1002_jha2_393
crossref_primary_10_1080_17474086_2019_1643232
crossref_primary_10_1016_j_blre_2018_03_005
crossref_primary_10_1002_hon_2928
crossref_primary_10_1016_j_ccell_2019_08_001
crossref_primary_10_1080_10428194_2019_1648805
crossref_primary_10_1002_iid3_616
crossref_primary_10_3390_jcm10081768
crossref_primary_10_1007_s11864_018_0569_2
crossref_primary_10_1111_bjh_16719
Cites_doi 10.1182/blood-2006-08-038257
10.1056/NEJMoa011795
10.1159/000088333
10.1093/annonc/mdr440
10.1023/A:1008394827806
10.1200/JCO.2008.16.8021
10.1200/JCO.2005.09.131
10.1093/annonc/mdh013
10.1093/annonc/mdf175
10.1182/blood-2002-06-1636
10.1200/JCO.2015.65.6520
10.1093/annonc/mdp432
10.1056/NEJM199309303291402
10.3109/10428194.2011.596966
10.1200/JCO.2010.31.4187
10.1182/blood-2008-10-182253
10.1093/annonc/mds621
10.1200/JCO.2015.63.1143
10.1097/CCO.0b013e3283499c7c
10.5581/1516-8484.20130063
10.1182/blood-2015-10-676700
10.3109/10428194.2014.931953
10.1111/j.1349-7006.2011.02139.x
10.1007/s00277-010-1150-7
10.1200/JCO.2003.11.141
10.3324/haematol.2008.005355
10.1002/cncr.26588
10.1111/j.1365-2141.2012.09247.x
10.1007/s12185-009-0289-2
10.1038/bmt.2012.244
10.1002/cncr.25278
10.1093/annonc/mdq627
ContentType Journal Article
Copyright 2017 Informa UK Limited, trading as Taylor & Francis Group 2017
Copyright_xml – notice: 2017 Informa UK Limited, trading as Taylor & Francis Group 2017
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1080/10428194.2017.1330541
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1029-2403
EndPage 104
ExternalDocumentID 10_1080_10428194_2017_1330541
28593796
1330541
Genre Original Articles: Clinical
Journal Article
GroupedDBID ---
00X
03L
0BK
0R~
29L
36B
4.4
53G
5GY
AAJNR
AALUX
AAMIU
AAPUL
AAPXX
AAQRR
ABBKH
ABDBF
ABEIZ
ABLKL
ABPTK
ABUPF
ACENM
ACFUF
ACGEJ
ACGFS
ACLSK
ADCVX
ADFCX
ADRBQ
ADXPE
AECIN
AENEX
AEOZL
AEXWM
AEYQI
AFKVX
AFWLO
AGDLA
AGFJD
AGRBW
AGYJP
AIJEM
AIRBT
AJWEG
AKBVH
ALIIL
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AMDAE
BABNJ
BLEHA
BOHLJ
CCCUG
CS3
DKSSO
DU5
EAP
EBB
EBC
EBD
EBS
EBX
EJD
EMB
EMK
EMOBN
EPL
ESX
F5P
H13
HZ~
J.N
KRBQP
KSSTO
KWAYT
KYCEM
LGLTD
M4Z
O9-
P2P
RNANH
RVRKI
SV3
TFDNU
TFL
TFW
TUS
UEQFS
V1S
~1N
5VS
AALIY
AAORF
ABLIJ
ABWCV
ABXYU
ABZEW
ACIEZ
ACKZS
ADFOM
ADFZZ
AEIIZ
AFLEI
AJVHN
ALYBC
AWYRJ
BRMBE
CAG
CGR
COF
CUY
CVF
CYYVM
CZDIS
DRXRE
DWTOO
ECM
EIF
HF~
JENTW
LJTGL
M44
NPM
NUSFT
QQXMO
TBQAZ
TDBHL
TERGH
TUROJ
UDS
Y6R
ZGI
ZXP
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c432t-64d44fe72b29d28b6e498077322c2b9cd19d5aa96b58a94e0a1149e7c1b785063
ISSN 1042-8194
IngestDate Fri Aug 16 06:11:27 EDT 2024
Fri Aug 23 02:53:35 EDT 2024
Sat Sep 28 08:40:36 EDT 2024
Tue Jun 13 19:58:43 EDT 2023
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords International prognostic index
diffuse large B-cell lymphoma
prophylaxis
R-CHOP
central nervous system
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c432t-64d44fe72b29d28b6e498077322c2b9cd19d5aa96b58a94e0a1149e7c1b785063
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 28593796
PQID 1907321958
PQPubID 23479
PageCount 8
ParticipantIDs informaworld_taylorfrancis_310_1080_10428194_2017_1330541
proquest_miscellaneous_1907321958
pubmed_primary_28593796
crossref_primary_10_1080_10428194_2017_1330541
PublicationCentury 2000
PublicationDate 2018-01-02
PublicationDateYYYYMMDD 2018-01-02
PublicationDate_xml – month: 01
  year: 2018
  text: 2018-01-02
  day: 02
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Leukemia & lymphoma
PublicationTitleAlternate Leuk Lymphoma
PublicationYear 2018
Publisher Taylor & Francis
Publisher_xml – name: Taylor & Francis
References CIT0030
CIT0010
CIT0032
CIT0031
CIT0034
CIT0011
CIT0033
CIT0014
CIT0013
CIT0016
CIT0015
CIT0017
Yamamoto W (CIT0012) 2010; 85
CIT0019
CIT0021
CIT0020
CIT0001
CIT0023
CIT0022
El-Galaly TC (CIT0018) 2015; 33
CIT0003
CIT0025
CIT0002
CIT0024
CIT0005
CIT0027
CIT0004
CIT0026
CIT0007
CIT0029
CIT0006
CIT0028
CIT0009
CIT0008
References_xml – ident: CIT0001
  doi: 10.1182/blood-2006-08-038257
– ident: CIT0002
  doi: 10.1056/NEJMoa011795
– ident: CIT0023
  doi: 10.1159/000088333
– ident: CIT0016
  doi: 10.1093/annonc/mdr440
– ident: CIT0005
  doi: 10.1023/A:1008394827806
– ident: CIT0006
  doi: 10.1200/JCO.2008.16.8021
– ident: CIT0003
  doi: 10.1200/JCO.2005.09.131
– ident: CIT0008
  doi: 10.1093/annonc/mdh013
– ident: CIT0004
  doi: 10.1093/annonc/mdf175
– ident: CIT0007
  doi: 10.1182/blood-2002-06-1636
– ident: CIT0017
  doi: 10.1200/JCO.2015.65.6520
– ident: CIT0011
  doi: 10.1093/annonc/mdp432
– volume: 85
  start-page: 6
  year: 2010
  ident: CIT0012
  publication-title: Eur J Haematol
  contributor:
    fullname: Yamamoto W
– ident: CIT0019
  doi: 10.1056/NEJM199309303291402
– ident: CIT0013
  doi: 10.3109/10428194.2011.596966
– ident: CIT0022
  doi: 10.1200/JCO.2010.31.4187
– ident: CIT0009
  doi: 10.1182/blood-2008-10-182253
– ident: CIT0029
  doi: 10.1093/annonc/mds621
– ident: CIT0031
  doi: 10.1200/JCO.2015.63.1143
– ident: CIT0026
  doi: 10.1097/CCO.0b013e3283499c7c
– ident: CIT0030
  doi: 10.5581/1516-8484.20130063
– ident: CIT0034
  doi: 10.1182/blood-2015-10-676700
– ident: CIT0024
  doi: 10.3109/10428194.2014.931953
– ident: CIT0015
  doi: 10.1111/j.1349-7006.2011.02139.x
– ident: CIT0014
  doi: 10.1007/s00277-010-1150-7
– volume: 33
  start-page: 171
  year: 2015
  ident: CIT0018
  publication-title: Hematol Oncol
  contributor:
    fullname: El-Galaly TC
– ident: CIT0021
  doi: 10.1200/JCO.2003.11.141
– ident: CIT0033
  doi: 10.3324/haematol.2008.005355
– ident: CIT0025
  doi: 10.1002/cncr.26588
– ident: CIT0028
  doi: 10.1111/j.1365-2141.2012.09247.x
– ident: CIT0010
  doi: 10.1007/s12185-009-0289-2
– ident: CIT0020
  doi: 10.1038/bmt.2012.244
– ident: CIT0027
  doi: 10.1002/cncr.25278
– ident: CIT0032
  doi: 10.1093/annonc/mdq627
SSID ssj0005962
Score 2.3119824
Snippet Central nervous system (CNS) involvement is a serious complication in patients with diffuse large B-cell lymphoma (DLBCL) and evaluating CNS risk is an...
SourceID proquest
crossref
pubmed
informaworld
SourceType Aggregation Database
Index Database
Publisher
StartPage 97
SubjectTerms Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols
central nervous system
Central Nervous System Neoplasms - epidemiology
Central Nervous System Neoplasms - mortality
Central Nervous System Neoplasms - prevention & control
Central Nervous System Neoplasms - secondary
Cyclophosphamide
diffuse large B-cell lymphoma
Doxorubicin
Female
Humans
Incidence
International prognostic index
Lymphoma, Large B-Cell, Diffuse - drug therapy
Lymphoma, Large B-Cell, Diffuse - epidemiology
Lymphoma, Large B-Cell, Diffuse - mortality
Lymphoma, Large B-Cell, Diffuse - pathology
Male
Middle Aged
Prednisone
Prognosis
prophylaxis
R-CHOP
Risk
Vincristine
Young Adult
Title The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis
URI https://www.tandfonline.com/doi/abs/10.1080/10428194.2017.1330541
https://www.ncbi.nlm.nih.gov/pubmed/28593796
https://search.proquest.com/docview/1907321958
Volume 59
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZC2MvY_emu6DB3oYzS77IemzSlTLSvCxlfTOSLTPTxg6JA2vZL9iv3pFkxc7WssuLMJYjx_m-HB0dn_MJoXfEz4qYFrkXJhE0IvI9IQPpsUiRpMiIoKZI7GwWn56Hny6ii8HgRy9radPIUXZza13J_6AK5wBXXSX7D8huB4UTcAz4QgsIQ_vXGG9jAeVObE_nXVW1FmF-bwQRTTrhcqVfyzSuQsqllU9mn-EisFNGO9zsGXA8HU-mJkir85Z1OaZOKdKjAixX4lu57nu1U7W5VItSGB5dXQNB6s7cz-tFaV3UmaibujMzl_W1WAhbMLQWX8tV1wfngUImivtFNGK16eL-8LhCKsuMdutvF7UgiYlaWLOrrKXVeTdaDLBviltx8D7lrF21Oby_mXubH0n0uo9wHSEjbASLbnBDSf96QG25MBzQcn0B47-Ib5vp3HXdQ_uU8QgW8vtH4-PxSZcwxGPqasAS_8Otd9Xa0u04O47Ojgzu3YsZ49TMH6GH7WoEH1lqPUYDVT1B98_afIun6DswDDuG4R2G4Y5h2DAMw61xxzAMDMOaYbguMDAM9xgGx9gwDLcMw45huMewZ-j85ON8cuq1-3V4WRjQxovDPAwLxaikPKeJjFXIE58xmDMyKnmWE55HQvBYRongofIFLMa5YhmRTAsnBs_RXlVX6gBhcENzv2AyibMijLNAslwUBRecgjMFc_QQjdyPmy6tLEtKWrVbB0yqgUlbYIaI9yFIGxMPK-zmNWnwh8--dXilYHz1GzVRqXqzTsGbhqfTek1D9MICuf06jgeHd_a8RA-6v8YrtNesNuo1uLiNfNNy7yfCbKVU
link.rule.ids 315,786,790,27957,27958
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+standard+international+prognostic+index+for+predicting+the+risk+of+CNS+involvement+in+DLBCL+without+specific+prophylaxis&rft.jtitle=Leukemia+%26+lymphoma&rft.au=Tomita%2C+Naoto&rft.au=Yokoyama%2C+Masahiro&rft.au=Yamamoto%2C+Wataru&rft.au=Watanabe%2C+Reina&rft.date=2018-01-02&rft.eissn=1029-2403&rft.volume=59&rft.issue=1&rft.spage=97&rft_id=info:doi/10.1080%2F10428194.2017.1330541&rft_id=info%3Apmid%2F28593796&rft.externalDocID=28593796
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1042-8194&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1042-8194&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1042-8194&client=summon